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Abstract: The use of blood-based eye drops as therapy for various diseases of the ocular surface
has become increasingly popular in ophthalmic practice during recent years. The rationale for
their use is based on the promotion of cellular proliferation and migration thanks to the supply of
metabolically active substances, in particular growth factors. Blood-derived eye drops have been
used for the treatment of several ocular surface disorders, such as dry eye disease, corneal ulcer,
persistent epithelial defect, neurotrophic keratitis, ocular surface burn, recurrent corneal erosion, and
limbal stem-cell deficiency. Both autologous (from patients themselves) and heterologous (from adult
donors or from cord blood sampled at birth)-derived products exist, and each source has specific
pros and cons. Despite an extensive literature, several issues are still under debate and the aim of
this manuscript is to review the indications, preparation methods and storage, characterization of
content, rationale for clinical outcomes, patient stratification, length of treatment, and rationale for
repeated treatments at disease relapse. A rationale based on a “5 Ws and 2 Hs” protocol is proposed
as a way of thinking, with the attempt to clarify Who, Why, When, Where, What, and How to use
these treatment options.
Keywords: dry eye; ocular surface disease; autologous serum; allogenic serum; cord blood serum;
platelet-derived eye drops
1. Introduction
Dry Eye Disease (DED) is “a multifactorial disease of the ocular surface characterized by a loss
of homeostasis of the tear film and accompanied by ocular symptoms, in which tear film instability
and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play
etiological roles” [1]. DED is common in the general population, increasing with age [2], and is one
of the most frequent occurrences in daily practice [3], with a substantial impact on the individual’s
quality of life [4]. Different modalities of treatment are available, with a proposed management
algorithm based on a sequence of treatments according to the stage of disease [5]. The prescription of
blood-derived products is recommended for the treatment of DED patients at stage 3 out of 4.
The usefulness of treatment with eye drops prepared from autologous blood was first described
in patients with chemical burns in the 1970s [6] and, ten years later, in patients affected by DED related
to Sjögren’s syndrome [7], becoming popular thereafter and increasingly introduced in ophthalmic
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practice with other blood-derived products. These consist of eye drops derived either from patients’
own peripheral blood (autologous source) or from donors (allogeneic source—adult or umbilical cord
blood) and prepared in the form of serum, platelet-rich plasma (PRP), plasma rich in growth factors
(PRGF), and platelet lysate (PL) [8,9].
Blood-derived eye drops contain different biochemical constituents that act more closely to natural
tears as compared to more conventional therapies [10,11], and the evidence of their effect on growth
and proliferation of corneal epithelial cells has been investigated by in vitro and in vivo studies [12–14].
An increasing number of peer-reviewed papers have been published over the last fifteen years, showing
the expanded indication for treatment, including mainly DED, persistent epithelial defect (PED), ocular
graft-versus-host disease (oGVHD), recurrent corneal erosion (RCE), neurotrophic keratitis (NK), and
limbal stem-cell deficiency (LSTD). Despite this extensive literature, there are still several issues under
debate related both to the lack of a standardised protocol for preparation and storage and to the absence
of consensus on the clinical strategy to achieve the best results, in particular, the rationale for clinical
outcomes, patients’ stratification, length of treatment, and the rationale for repeated treatments.
The aim of this manuscript is to review the indications, preparation methods, and clinical efficacy
of blood-derived products used in ophthalmological practice, with a particular focus on unmet needs,
current challenges, and future directions in clinical practice.
2. The Rationale for Use of Blood-Derived Eye Drops
The “Ocular Surface System” includes the epithelia of cornea and conjunctiva, the limbus
(junctional zone in between), the lachrymal and meibomian glands, the tear film, the eyelids, and
the nasolacrimal duct. All components are functionally integrated and linked by the integrity of the
corneal epithelium; by innervation; and by the endocrine, vascular, and immune systems [15].
The cornea is a transparent avascular tissue, accounting for approximately two-thirds of overall
refractive power, with a metabolism strictly dependent upon diffusion of oxygen and nutrients
from the tear film anteriorly and the aqueous humour posteriorly. The integrity of the corneal
epithelium is enabled by self-renewing stem cells, located in the limbus at the Palisades of Vogt,
which persists throughout its lifetime. The activity of corneal epithelial stem cells (CSCEs) is finely
regulated by the surrounding niche. Moreover, different factors contained in the tear film are regulated
by paracrine/autocrine pathways to allow maintenance of fundamental functions, such as cellular
replacement and wound healing [16].
An increasing interest in the application of human-blood-derived products such as eye drops
for DED arose over the last years. Serum is the most common blood product used as eye drops,
which is obtained by the physiological clotting process of blood collected without an anticoagulant.
The therapeutic benefits of blood-derived serum eye drops (SED) may be explained by a composition
similar to that of tears [17–19]. SED contains carbohydrates, lipids, and various electrolytes like tears,
a ten-fold higher total concentration of protein, and a mixture of epitheliotrophic growth factors [20,21]
released by platelet alpha-granules degranulation that occurs during clotting [22].
Different types of growth factors (GFs) such as epidermal growth factor (EGF), fibroblast growth
factor (FGF), transforming growth factor-beta (TGF-β), nerve growth factor (NGF), platelet-derived
growth factor (PDGF), and insulin-like growth factor (IGF) and their receptors expressed in corneal
epithelial cells, keratocytes, endothelial cells, and CSCEs stimulate turnover and proliferation of corneal
cells and play a main role in maintaining ocular surface integrity [23,24]. To discuss the respective
roles of these GFs is beyond the purpose of this manuscript, and readers are referred to reviews on this
issue [25,26]. Finally, a reflection should be made on the continuous supply of such growth factors to
the surface and, in particular, to the CSCEs which can undergo overstimulation, as it can be suggested
by in vitro experiments. For instance, EGF increases proliferation of human corneal epithelial cells in a
dose-dependent manner at concentrations greater than 0.1 ng/mL, but at concentrations exceeding
10 ng/mL, the cellular proliferation is reduced [23,27].
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Therapeutic constituents of blood can be prepared by centrifugation, filtration, and freezing, all
procedures which can influence the quality of the final product, also in terms of GF content. As the main
focus is nowadays on using the specific component that is clinically indicated, processing procedures
should be detailed and harmonized with an attempt to provide standardized blood products as the
best of the existing options. For now, processing procedures are published and annually revised under
the supervision of the European Directorate for the Quality of Medicines and HealthCare (EDQM;
downloaded freely from https://www.edqm.eu/en/blood-guide) in the European Union. In the United
States, blood and blood products are under the surveillance of the Food and Drug Administration
(FDA; https://www.fda.gov/vaccines-blood-biologics/blood-blood-products). In Italy, according to the
current legislation, recommendations for non-transfusional use of blood products is published by the
Italian Society for Transfusion Medicine (SIMTI) [28].
3. Literature Review
3.1. Search Strategy
We searched PubMed, Embase, Web of Science, Ovid, Cochrane Database, and Scopus databases
for original articles published up to 31 May 2019, using the keywords (all languages)(“Clinical trial*”
OR “autologous serum*” OR “allogenic*” OR “cord blood*” OR “umbilical blood*” OR “PRP”) AND
(“keratopathy” OR “dry eye” OR “neurotrophic keratitis” OR “corneal ulcer” OR “epithelial defect”)
without any limitation. Moreover, reference lists of retrieved studies were manually scanned for
all relevant additional studies and review articles. The searches were conducted by 3 independent
investigators (F.B., M.P., and M.R.). Any discrepancies were resolved by discussion or by input from
another reviewer (P.V.).
3.2. Study Selection
After removing duplicates, 2 authors (F.B. and P.V.) individually screened titles and abstracts
of all identified citations. The full text of citations deemed as potentially eligible were obtained and
individually screened for eligibility, and any disagreement was discussed with all authors.
3.3. Eligibility Criteria
The articles were considered eligible if the studies met the following inclusion criteria: (1) study
type: randomized controlled trial (RCT), retrospective; (2) population: patients having DED of any
etiology, NK, PED, and RCE. Exclusion criteria were as follows: (1) lack of clinical data reporting;
(2) types of publications other than original articles (e.g., abstracts from congresses, letters to editors,
correspondence, reviews, duplicates, and full texts without raw data available for retrieval).
3.4. Data Extraction
Three reviewers (F.B., M.R., and M.P.) independently extracted the following data from each
included publication: first author name, year of publication, design of the study, condition treated,
inclusion criteria, number of patients and control subjects (if applicable), control arm product, solvent
composition and dilution of the blood-based product, posology and duration of treatment, main
outcomes, results, and retreatment parameters (rationale, cycles, time interval of treatment suspension,
and total duration of treatment).
Studies with data reported in figures or with missing data were excluded. In case of disagreement
among the 2 reviewers, full texts were revisited and agreed on by discussion.
3.5. Quality Assessment
All selected studies were graded according to the modified American Academy of Ophthalmology
Preferred Practices guidelines [29] as follows. Level 1: Evidence obtained from at least one properly
conducted, well-designed, randomized, controlled trial or evidence from well-designed studies
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applying rigorous statistical approaches. Level 2: Evidence obtained from one of the following:
a well-designed controlled trial without randomization; a well-designed cohort or case-control analytic
study, preferably from one or more center; or a well-designed study accessible to more rigorous
statistical analysis. Level 3: Evidence obtained from one of the following: descriptive studies, case
reports, reports of expert committees, and expert opinion.
4. Autologous Serum Eye Drops
Serum is the component remaining after clotting of whole blood, and it contains many of the
factors present in tears. Autologous SED (auto-SED) is obtained from patients’ own peripheral blood
serum. Production methods including clotting time, centrifugation parameters, dilution, storage time,
and temperature were shown to determine quality and characteristics of the final dispensed product,
but no consensus on technical details for the preparation of auto-SED have been established so far.
Hence, the formulation and dilution factor of SED for DED treatment largely rely on the experience of
single blood centers according to national or regional blood establishments, as was discovered in a
recent survey conducted by the Biomedical Excellence for Safer Transfusion (BEST) Collaborative on
methods used at international levels to prepare SED [30].
The several studies reviewed followed, with light differences, the basic protocol proposed by
Liu [31] and others. Briefly, 50–100 mL of whole blood is taken from the patient and is left for 2 h at
room temperature until complete clotting is reached. Then, the blood is centrifuged at 3000 g for 15 min
to completely separate serum from solid constituents. Next, balanced salt solution (BSS) or isotonic
saline solution is added to the supernatant until the desired concentration is reached. Allo-SED has to




The BEST survey reported that almost half of the centers dilute serum before dispensing in order to
reduce to a physiologic concentration the levels of potentially anti-proliferative factors, such as TGF-β,
which has shown to slow down corneal healing and to facilitate corneal stromal fibrosis and opacity
in vitro [23,32]. Indeed, it has been shown that TGF-β plays a main role in the development of mature
myofibroblasts during corneal healing after injury, producing a disorganized extracellular matrix in
the stroma that results in loss of transparency [33]. Nevertheless, serum dilution leads to decreased
levels of trophic factors, potentially limiting its beneficial effects. A recent Cochrane, which reviewed
four clinical trials on auto-SED, reported the use of 20% dilution in all the studies [34]. Several studies
investigated the use of higher concentrations (50 to 100%), reporting an excellent clinical efficacy
and no adverse effect [35–38]. Moreover, other authors proposed to dilute SED to 20% in a sodium
hyaluronate solution to improve retention time and to decrease the frequency of administration and
reported good results. [39]. Given these evidences, it cannot be excluded that formulation may have to
be adjusted to the treated disease or to its extent.
4.1.2. Storage
Significant differences were reported in terms of recommended maximal storage time for serum
drops, in part, due to internationally varying laws/regulations. It has been reported that several
serum GFs are temperature and time resistant but substance P and calcitonin gene-related peptides
significantly degrade at 4 ◦C within 24 h [40]. Hence, it is important to store serum vials frozen to
preserve the activity of epitheliotrophic factors [41], which have been shown to be maintained until a
prolonged storage of 6 months at −20 ◦C [42].
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4.1.3. Safety
Exposure to contaminated SED should be avoided, especially in DED patients who have a higher
risk of developing infections because of their diseased surface. SED are prepared based on the
guidelines for good manufacturing practice (GMP) [43], generally in open systems with a remote but
still potential risk of contamination during the manufacturing process. Very few cases of adverse events
related to contamination have been reported in the literature (reviewed in Reference [44]). To improve
safety, sealed manufacturing systems (which package the eye drops into vials or long lengths of tubing,
which are then heat-sealed to produce single-use devices) have been proposed in the market [45–47],
but financial and logistic barriers are still unaffordable in many centers [48].
4.2. Clinical Results
Six RCTs investigated the efficacy of auto-SED for the treatment of severe DED (Table 1) [49–54].
Improvement of symptoms and signs (tear breakup time (TBUT), corneal staining, and conjunctival
impression cytology) was reported in severe DED patients after therapy with auto-SED and tear
substitutes with [50,51] or without [49] significant differences between the groups. In a cross-over
study, severe DED patients were randomized to receive 3 months of treatment with auto-SED 50% and
3 months with conventional therapy, and viceversa; symptoms and impression cytology of conjunctival
epithelial cells improved more significantly after treatment with auto-SED [50]. Two recent cross-over
trials on severe DED reported a higher decrease of symptoms score in the auto-SED group compared to
the control group treated with tear substitutes [52,53]; nevertheless, a significant improvement of TBUT
was also reported in the auto-SED group only in the study from Celebi [53]. Yilmaz et al. reported a
significant magnitude of the mean improvement of symptoms and TBUT in patients with DED due to
systemic isotretinoin after auto-SED therapy compared to those treated with tear substitutes [54].
Several non-randomized studies evaluated the efficacy of auto-SED in DED of different aetiologies.
Ogawa et al. investigated the use of auto-SED in patients affected by oGVHD, reporting a significant
improvement of symptoms, TBUT, and corneal staining [55]. Two prospective studies evaluated the use
of auto-SED in patients affected by primary and secondary Sjögren Syndrome (SS), with an improvement
of both signs and symptoms only in patients with primary SS [56] or of only symptoms [57]. Both
undiluted and diluted 20% auto-SED seem to ameliorate DED related to SS. In particular, Cho et al. [37]
treated patients with SS DED (not distinguishing between primary and secondary), non-SS DED, and
PED with undiluted auto-SED, 50% auto-SED in saline, or 50% auto-SED in sodium hyaluronate,
reporting different results for different aetiologies. Jirsova et al. [58] treated DED associated with
primary Sjögren, secondary Sjögren, sarcoidosis, and unknown aetiologies with 20% auto-SED in saline
and reported significant improvements of clinical findings and symptoms occurring in 77% and 63% of
eyes, respectively, but they did not stratify patients according to aetiology.
López-Garcia et al. [39] treated SS DED (not distinguishing between primary and secondary) with
20% auto-SED in saline or 20% auto-SED in sodium hyaluronate and compared the efficacy of two
different dilution vehicles for auto-SED delivery. They demonstrated that both sodium hyaluronate
and saline determine a significant improvement of tear-film stability, corneal staining, TBUT, and
symptoms but without significant differences.
The potential efficacy of auto-SED treatment was investigated also in other ocular surface
diseases, in particular NK, PED related to different causes (i.e., post refractive surgery, post perforating
keratoplasty, and other ocular surgery), RCE, and LSCD (Limbal Stem Cell Deficiency) [59–65].
In a retrospective case series, auto-SED treatment for NK refractory to conventional therapy
lead to complete healing in 100% of patients and to an improvement of corneal sensitivity in 64%
of patients [59]. A large prospective study evaluated undiluted auto-SED treatment for PED due to
different types of ocular surgery and reported a complete corneal healing in more than 90% of patients
on an average of 4 days [63]. In a case-controlled study on pterygium surgery, auto-SED promoted a
faster corneal re-epithelialization as compared to tear substitutes [64].
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A randomized trial compared auto-SED treatment with tear substitutes after laser in situ
keratomileusis (LASIK) and reported an improvement in TBUT and rose bengal staining in the
auto-SED group, with no difference in symptom scores between groups [60].
In a large case-controlled study that compared auto-SED with tear substitutes after PK, patients who
received auto-SED showed a significant improvement of corneal re-epithelialization time. Moreover,
the efficacy of auto-SED was reported even in difficult cases such as larger-diameter grafts and diabetic
patients [65].
Schulze et al. compared autologous serum therapy with hyaluronic tears in diabetic patients
undergoing pars plana vitrectomy who received corneal abrasion for better intraoperative
visualization [61]. Patients treated with auto-SED showed a significant improvement of the closure of
corneal epithelium compared to the control group [61].
A prospective study investigated auto-SED treatment in patient RCE refractory to standard
therapy. After auto-SED treatment, complete corneal healing was reported in 100% of cases, and in 85%
of cases, no relapse occurred during the following 12 months. [62]. Auto-SED treatment in 13 patients
affected by LSCD due to aniridia lead to an improvement of tear stability, corneal epithelialization, and
symptoms [66].
Although the encouraging results reported in the RCTs on the efficacy of auto-SED therapy for
severe DED, a Cochrane meta-analysis published in 2013 and based on 4 auto-SED RCTs showed an
overall inconsistency in patient’s reported symptoms and lack of effect based on objective clinical
measures, concluding that high-quality RCTs are warranted to assess the benefits of this treatment
in DED [34]. The 21 studies on auto-SED included in the present review had levels of evidence 1
(9 studies) or 2 (11 studies) and only one study had level 3, with only 11 studies analyzing auto-SED
with a comparator, generally unspecified tear substitutes. In agreement with the Cochrane report,
however, the inconsistency of measures and standardized preparation prevent a conclusive statement
on auto-SED efficacy as compared to conventional treatments.
5. Allogeneic Adult Peripheral Blood Serum Eye Drops
The rationale for the use of SED prepared from donor sources is now driven by the assumption of
negative effects caused by serum-derived autoantibodies or pro-inflammatory cytokines that would be
deliberately applied to the ocular surface in patients with important comorbidities. Peripheral blood
from adult donors and cord blood sampled from umbilical veins at birth are now eligible candidates
for allogeneic sources. Although SED of autologous origin is still the most manufactured product, an
increasing number of centers worldwide is now producing SED from allogeneic blood donors [67–75].
When the SED are from allogeneic origins, procedures must be undertaken to match all blood groups
to ensure hemato-immunological ABO antigen matching between donors and recipients. One option
could be to prepare SED from AB group donors to hold a single blood group source, but the limited
prevalence of the AB group in the Caucasian population may limit the availability of this source.
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Table 1. Summary of studies related to Auto-SED. Legend: Auto-SED = Autologous serum eye drops; CIC = Conjunctival impression cytology;
CMC = Carboxymethylcellulose; d = day; DED = Dry eye disease; FS = Fluorescein staining; GVHD = Graft versus host disease; I = interventional; ISS = Isotonic
Saline Solution; LASIK = Laser assisted in situ keratomileusis; M = Month; NaHy = Sodium hyalutonate; NK = Neurotrophic keratitis; OSDI = Ocular Surface
Disease Index; P = Prospective; PED = Persistent epithelial defects; PK = Penetrating Keratoplasty; RCT = randomized controlled trial; RBS = Rose Bengal staining;
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The use of allogenic serum obtained from healthy donors has been introduced as a possible
alternative to auto-SED in patients with inaccessible peripheral venous access or use of anticoagulant
medications or coexisting systemic diseases such as coagulation factor deficiency and haematological
disease. Moreover, some authors reported that peripheral serum of SS and oGVHD patients that
represent two of the most common causes of severe DED might contain high concentrations of
pro-inflammatory mediators potentially harmful to the ocular surface [76], although others disagree [45].
In addition, it has been shown that other diseases are associated with an altered serum composition
that presents significantly decreased epitheliotrophic properties, in particular, in patients with chronic
renal failure and rheumatoid arthritis [77,78]. Other disadvantages of auto-SED are that some people
fear venipuncture and the prolonged treatment, and the frequent drawing of blood can be inconvenient
in others. Cultural considerations also play some role as, in Asian cultures, the belief is held that
frequent blood sampling increases weakness and susceptibility to infections [69].
Preparation methods of allogeneic SED (allo-SED) are the same as that of auto-SED. The whole
blood is taken and stored at room temperature until it is clotted. Next, serum is separated by
centrifugation at 3000 g for 15 min, filtered, and diluted to 20% concentration [36]. Allogeneic blood
donors donating blood for the production of SED should be screened for virus markers using the same
procedures that are applied to donations used for transfused blood products [30,43,79].
The use of allo-SED also poses some issues related to legal or ethical concerns [80], and a written
informed consent is required in many legislations.
Clinical Results
Table 2 reports the list and details of the main studies related to the use of allo-SED.
Chiang et al. [69] investigated the use of allo-SED in patients affected by PED due to different
causes, including penetrating keratoplasty (PK), NK, oGVHD, and exposure keratopathy, that were
refractory to standard treatment. Relatives donated blood for the preparation of allo-SED that was
used at a concentration of 100%. Almost half of the treated patients showed complete healing within
2 weeks that was reached in 63.9% of patients within 4 weeks.
Allo-SED efficacy was evaluated also in patients with DED related to oGVHD. In particular, after
four weeks of treatment with 20% allo-SED obtained from healthy donors, a significant decrease in
symptoms score, tear osmolarity, corneal staining, and TBUT was noted [72]. Furthermore, another
study reported a significant improvement in symptoms and ocular surface parameters in 2 oGVHD
patients treated with allo-SED [70].
Harritshøj et al. evaluated the efficacy of allo-SED 20% prepared from blood of identical ABO
groups in patients affected by both DED and PED [71]. They showed a significant improvement in
symptoms and signs in the DED group, while no significant changes were the PED group.
A randomized, double-blind study on DED patients evaluated comparatively by confocal
microscopy the effect on the corneal sub-basal nerve plexus of a one-month treatment with two
allogeneic products, namely peripheral blood serum from adult donor or umbilical cord blood serum
(UCBS) eye drops [81]. Overall, both treatments significantly improved corneal sub-basal nerve plexus
parameters, with a superiority for UCBS drops associated with a higher increase of the corneal nerve
fractal dimension global metric.
Since 2007, 39% of all SEDs issued in New Zealand have been allogeneic [68], and a cross-over
retrospective study was recently reported [74], dealing with a comparison of autologous and allo-SED
in patients who served as their own controls. Results demonstrated a comparable efficacy and
tolerability in both products, and most of those who changed from autologous to allo-SED reported
either maintained benefits or further improvement, but a prospective randomized trial is now needed
to confirm this observation.
J. Clin. Med. 2019, 8, 1478 11 of 29
Table 2. Summary of studies related to Allo-SED from adult donors. Legend: Allo-SED = Allogenic serum eye drops; CMC = Carboxymethylcellulose; d = day;
DED = Dry eye disease; FS = Fluorescein staining; GVHD = Graft versus host disease; I = interventional; ISS = Isotonic Saline Solution; OSDI = Ocular Surface Disease
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6. Allogeneic Umbilical Cord Blood Serum Eye Drops
Umbilical cord blood serum is collected from mothers during both vaginal and caesarean delivery.
An informed consent must be signed prior to performing the blood collection. From 10 to 20 mL of the
umbilical cord blood is collected from the umbilical vein after delivery. The blood is clotted for 2 h at
room temperature; after centrifugation at 3000 rpm for 15 min, the serum is isolated carefully under
sterile conditions in a laminar air flow hood. Then, 20% concentration is reached by the dilution with
BSS. The serum is aliquoted into sterile 1-mL vials with ultraviolet light protection. Sealed eye drop
vials are stored in a freezer at −20 ◦C for a maximum of 3 months, and opened bottles are kept in a
refrigerator at 4 ◦C [46]. To avoid the transmission of blood-borne diseases, tests for HCV, HBV, HIV,
syphilis, toxoplasma, and CMV have to be performed.
As for allo-SED, UCBS represents a possible therapy for patients affected by systemic disease or
other conditions that may contraindicate the use of auto-SED due to the presence of inflammatory
mediators in the serum of the same. UCBS has a higher concentration of GF, such as EGF, TGF-β, NGF,
and VEGF, compared to other blood derived preparations [46,82–84]. Nevertheless, UCBS contains
a lower level of IGF-1 and vitamin A compared to peripheral blood serum but higher compared to
tears [83]. It has been shown that blood samples collected from young mother (<30 years) has a
higher concentration of EGF, along with longer labour duration (>6 h), and higher CD34+ cell content
(0.05 × 106/mL). This pre-selection may be helpful to obtain UCBS with the ideal concentrations in EGF
for healing corneal wounds without the need of GF laboratory dosages [85].
Clinical Results
UCBS eye drops were investigated as possible therapy of DED [46,82,86], PED [87–90], acute
chemical burns [91,92], oGVHD [93], RCE [94], after PK [95], laser epithelial keratomileusis (LASEK) [96],
Hansen’s disease [97], and NK [98,99] (Table 3). A significant reduction of subjective discomfort
symptoms associated with an improvement of tear stability, and recovery of the corneal sensitivity
and keratopathy after UCBS treatment was shown in all studies in severe DED patients, with a high
degree of satisfaction upon instillation. PED refractory to previous medical management [87–89]
showed faster healing, no recurrence three months after the end of UCBS treatment, and higher increase
of goblet cell density as compared to autologous serum treatment in SS patients [90]. UCBS also
was shown to significantly ameliorate sub-basal corneal nerve morphology by an in vivo confocal
microscopy study, suggesting a role of neurotrophic factors contained in UCBS [84] in its mechanism
of action. These positive results were confirmed also in severe DED associated with oGVHD, in which
symptom score, corneal sensitivity, TBUT, and keratoepitheliopathy score improved significantly after
2 months of UCBS treatment, and the improvements were maintained by 6 months after treatment [93].
The treatment with UCBS was compared to auto-SED [91] and amniotic membrane [92] treatments in
patients with ocular chemical burns, showing a higher effectiveness in the ocular surface restoration
and, in particular, in complete re-epithelialization already after 3 ± 4 weeks and reduced corneal haze.
Yoon et al. evaluated the efficacy of UCBS in patients affected by RCE, reporting a mean healing time
of 4 weeks and a reduced number of recurrences [94]. UCBS seems to be useful in the treatment of NK
as it contains high levels of neurotrophic factors such as substance P, IGF-1, and NGF. In particular,
a study on 28 eyes with NK reported complete epithelial defect healing in all eyes, with a mean healing
time of 4.4 ± 4.0 weeks [98]. UCBS was also used in adjunct to conventional treatments after LASEK
and was successful in reducing the early postoperative corneal haze and in improving tear film and
ocular surface parameters [96]. Both auto-SED and UCBS treatments were effective in restoring the
tear proteomic profile and conjunctival cytology in DED associated with leprosy [97], which includes
corneal anaesthesia and severe epithelial squamous metaplasia. The UCBS treatment was proven in
maintaining longer these beneficial effects after treatment.
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Table 3. Summary of the studies on the use of UCBS. Legend: Auto-SED = Autologous serum eye drops; AMT = Amniotic membrane transplantation; BSS: Balanced
salt solution; CIC = Conjunctival impression cytology; CMC = Carboxymethylcellulose; d = day; DALK = Deep anterior lamellar keratoplasty; DED = Dry eye
disease; FS = Fluorescein staining; GVHD = Graft versus host disease; I = interventional; ISS = Isotonic Saline Solution; LASEK = laser epithelial keratomileusis;
M = Month; OSDI = Ocular Surface Disease Index; P = Prospective; PED = Persistent epithelial defects; PK = Penetrating Keratoplasty; RCT = randomized controlled
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7. Platelet Derived Eye Drops
Platelets play a main role in the wound healing process, since they have high concentrations of
GFs and cytokines contained in their α-granules, such as PDGF, TGF-β, and platelet factor IV [100].
Platelets-based preparations are extremely versatile; exist under forms of variable solidity from
liquid to gel; and have been largely used in regenerative medicine, orthopaedic and maxillo-facial
surgery in order to promote tissue healing through the delivery of several bioactive factors [22]. Various
preparations (namely PRP, PRGF, and platelet lysate) have quite recently been introduced as possible
therapy of different ocular surface disorders.
In platelet-derived eye drops, the autologous source still represents the most used product in DED
patients, whereas allogeneic PRP, developed for other fields of application, is still at its beginning as an
eye-drop treatment.
7.1. Preparations
There is a large heterogeneity among PRP separation systems regarding concentrations of platelets,
leukocytes, and growth factors in PRP. The choice for the most appropriate type of PRP should be
based on the specific clinical field of application. For each preparation, we detail below the most used
in the treatment of DED, as they appear in the literature.
Platelet-rich plasma is obtained from plasma that has a platelet concentration of over 1 × 106/mL.
Thirty mL of the patient’s venous blood is drawn in tubes with 3.2% sodium citrate in order to prevent
platelet activation prior to its use. A first centrifugation with low forces (10 min at soft spin from 200 g
to 600 g) separates the whole blood into three layers: an upper layer that contains mostly platelets
and white blood cells (WBC) called platelet-poor plasma (PPP); an intermediate thin layer of whitish
color called buffy coat (BC), rich in WBC; and a bottom layer that consists mostly of red blood cells
(RBC). The upper layer and superficial buffy coat are transferred into another sterile tube for a second
centrifugation step at higher speeds (10 min at hard spin from 700 g to 2300 g) to concentrate platelets.
The upper two-thirds of the volume (PPP) is discarded, while the lower one-third (5 mL of plasma) is
homogenized by gently shaking the tube to create PRP. The product can be used either undiluted or
diluted in BSS, sealed in vials or bottles, stored in the refrigerator at 4 ◦C for a maximum of 1 week
or at −20 ◦C for longer periods. PRP acts by stimulating the release of PDGF, that is the first growth
factor involved in the wound healing, and of TGF. Platelet-derived growth factor determines the
increase of activated macrophages along with the development of new blood vessels. Transforming
growth factor is able to induce chemotaxis and to control the epithelial proliferation, maintaining
cells in an indifferent state. Furthermore, other important factors are the EGF that accelerates corneal
epithelial proliferation and vascular endothelial growth factor (VEGF) and FGF-2 that take part in the
angiogenesis process [101].
Plasma rich in growth factors. In the literature, a specific procedure is found, patented to
standardize the PRGF preparation. Collected blood is centrifuged at 580 g for 8 min at room
temperature in an Endoret System centrifuge (BTI Biotechnology Institute, S.L., Minano, Alava, Spain).
The whole column of PRGF is collected after centrifugation using the Endoret ophthalmology kit (BTI
Biotechnology Institute), avoiding the buffy coat that contains the leukocytes. The PRGF eye drops are
incubated at 37 ◦C for 1 h; the obtained supernatant is then heat-treated at 56 ◦C for 60 min to eliminate
the complement fractions and other immunologic components and to obtain the so-called “immunosafe
PRGF”. Finally, plasma supernatants are filtered, aliquoted, and stored at −20 ◦C. Before starting
treatment, patients are taught to preserve the PRGF eye drops at −20 ◦C for maximum 3 months and to
use each dispenser for 3 consecutive days [102].
Platelet lysate—Sixty mL of anticoagulated peripheral blood is collected from each patient and
centrifuged to obtain an autologous platelet concentrate. The concentrate (at 0.7 × 106/mL) is frozen and
thawed (thermal shock −80 ◦C/+37 ◦C) to lyse platelets and GF release. The lysate is then diluted with
sterile, balanced saline solution (30% v/v) and aliquoted as 30 ready-to-use, sterile doses (ColSystem,
Biomed Device Modena, Italy). A sample for microbiological investigations is taken at the time of
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preparation. Next, the final preparation is frozen at −20 ◦C and stored in the patients’ own freezer for a
maximum of 45 days [103,104].
7.2. Clinical Results
Table 4 summarizes the characteristics and the main outcomes of clinical studies on the use of
platelet-derived products for the treatment of ocular surface diseases. Fluorescein staining improved
significantly in 72% of patients. The efficacy of PRP for the treatment of DED was investigated by
Alio et al. who reported an improvement of symptoms in 89% of patients and a gain of at least 1 line of
best-corrected visual acuity in 28% of cases. Furthermore, 56% of patients had improvements in the
tear meniscus height from low to normal level; 86% of patients showed a significant improvement of
conjunctival hyperaemia in slit-lamp appearance; and finally, fluorescein staining improved significantly
in 72% of the cases [105]. The same research group treated with PRP 26 eyes suffering from post-LASIK
DED, with improvements in symptoms in 85% of patients and a gain of 1–2 lines of best-corrected visual
acuity in 54% of them [106]. Alio et al. also employed topical PRP eye drops in 26 eyes with chronic
non-healing corneal ulcers and reported healing of the ulcer in half of the eyes and improvement in
inflammation and subjective symptoms in all of them [107].
Lopez-Plandolit used autologous plasma rich in PDGFs in 20 eyes affected by PED unresponsive
to conventional treatment, reporting healing of the epithelial defects in 85% of cases after a mean
therapeutic time of 10.9 weeks [108]. In another study, patients with ocular oGVHD unresponsive to
conventional therapy were treated with autologous plasma rich in PDGF eye drops. Photophobia
and TBUT improved in 82.6% and 86.9% of patients, respectively [109]. In 2017, the same authors
evaluated the long-term efficacy of plasma rich in PDGF eye drops in 31 patients with oGVHD.
After 36 months, symptoms and TBUT significantly improved and no adverse events occurred [103].
Kim et al. compared the healing efficacy of allo-SED and PRP in 28 eyes affected by PED and reported
a higher healing rate in the group treated with PRP [110]. A randomized controlled trial on 20 eyes
affected by grade III to V chemical injuries compared PRP eye drops with standard medical treatment
or standard medical treatment alone. After 3 months of treatment, significantly higher improvements
in corneal transparency and in visual acuity were found in patients who received PRP [111].
In an in vivo confocal microscopy study, Fea et al. reported a significant increase in basal
epithelium cells density and sub-basal nerve plexus density and a decrease in Langerhans cell density
in patients with SS-related DED treated with platelet lysate [112]. Lee et al. compared the efficacy of
PRP eye drops and tear substitutes in patients with RCE and found a significantly lower frequency of
recurrence in eyes receiving PRP eye drops [113].
Merayo-Lloves et al. evaluated the safety and efficacy of autologous plasma rich in PDGF eye
drops in 83 patients with evaporative DED and reported a significant improvement in symptoms,
best-corrected visual acuity, and Schirmer test [114]. The same research group investigated the use of
PDGFs in patients with SS-related DED [102], NK [115], post-LASIK DED [116], and oGVHD [117].
Patients with SS-related DED showed a significant improvement in symptoms and best-corrected visual
acuity after treatment [102]. Patients with DED following LASIK surgery showed an improvement in
symptoms and Schirmer test after treatment [116]. Patients with oGVHD showed an improvement of
symptoms, corneal staining, best-corrected visual acuity, TBUT, and Schirmer test [117].
A complete resolution of corneal ulcer was reported in 97.4% of patients with NK after a mean time
of 11.4 weeks [115]. Similar results were obtained in 25 NK patients treated by Wróbel-Dudzinska et al.
with PRP eye drops, with complete healing of the corneal ulcer observed in 80% of patients, while
improved symptoms and visual acuity observed in all of them [118]. In a randomized clinical trial,
Garcia-Conca et al. compared PRP eye drops with tear substitutes in patients with hyposecretory
DED [119]. Patients treated with PRP showed a significantly higher improvement in symptoms,
visual acuity, conjunctival hyperaemia, corneal and conjunctival staining, Schirmer test, and tear
osmolarity [119].
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Table 4. Summary of the studies on the use of preparations from PRP (Platelet-Rich Plasma); PL = Platelet Lysate; PRGF = Platelet Rich in Growth Factors. Legend:
Allo-SED = Allogenic serum eye drop; AMT = Amniotic membrane transplantation; CIC = Conjunctival impression cytology; d = day; DED = Dry eye disease;
GVHD = Graft versus host disease; I = interventional; ISS = Isotonic Saline Solution; LASIK = Laser assisted in situ keratomileusis; M = Month; NaHy = Sodium
hyalutonate; NK = Neurotrophic keratitis; OSDI = Ocular Surface Disease Index; P = Prospective; PED = Persistent epithelial defects; PRGF = plasma rich in growth
factors; PRP = Platelet rich plasma; PL = Platelet lysate; RCT = Randomized controlled trial; RBS = Rose Bengal staining; SS = Sjogren’s syndrome; ST = Schirmer test;
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Due to its versatile methods of preparation, PRP can be used also as a solid preparation during
reconstructive surgery of the ocular surface. A solid clot of PRP was used in combination with other
surgical techniques, such as amniotic membrane transplantation and bovine pericardium membrane
(Tutopach), to treat corneal ulcers and corneal perforations [120]. In a randomized controlled clinical
trial, Avila et al. evaluated the administration of PRP as an injectable solution into the lacrimal gland
in patients with SS-related DED. Compared to the control group, the intervention group showed a
higher improvement in corneal staining, Schirmer test, TBUT, and symptoms [121].
8. Data Analysis and Criticism
Regulations vary from country to country for the use of blood-derived eye drops, which are
classified differently according to local legislations—ranging from an unlicensed medicinal product
(“special”) to “simple” blood component—with variable degrees of restrictions.
Clinical recommendations on SED for severe ocular surface disease have been published by the
Royal College of Ophthalmologists [122,123], with the proposal to regulate SED by enrolling patients
in a national program of outcome reporting that includes frequency and duration of treatment, serious
adverse events or reactions, and patient self-reported outcomes. In this report, a 50% dilution in 0.9%
sodium chloride is recommended (as provided by National Health Service Blood and Transplant, the
only accredited SED production facility in the UK), only based on good practice points upon consensual
expert opinion.
Data from our work were extracted from 55 papers of level of evidence 1 (n = 17) and 2 (n = 32),
and only 6 papers were graded as level 3. All blood preparations used so far have been included for
all sources and preparations of blood based treatments for ocular surface disease: auto-SED (n = 20,
Table 1); adult allo-SED (n = 3, Table 2); allogeneic UCBS eye drops (n = 15, Table 3); allogeneic platelet
products (n = 17, Table 4) subdivided into PRP (n = 9); platelet lysate (n = 3); and PRGF (n = 5).
All studies showed a good profile in terms of safety and efficacy for all the products.
The list of ocular surface diseases treated with blood-based eye drops spans several conditions of
different aetiology and is summarized in Figure 1. We were not able to find any information about the
rationale for the product selection based on a specific condition or graded according to severity.
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Data highlights the elevated heterogeneity of processing of blood-based eye drops despite the
assumption that any procedure in the preparation may impact the content of the active substances or
may influence their delivery. Sterile saline was the most used diluent, and it was reported in 43 out of
55 studies. The alternative use of sodium hyaluronate or carboxymethyl cellulose or unspecified tear
substitutes were reported in 8 out of 55 studies with the aim to improve the retention time of the product
or to increase its availability, but results were too few and inconsistent to provide comparable data.
Dilution 20% was the most used percentage, reported in 31 out of 55 studies, followed by 50%
(7 studies) and undiluted (3 studies). The rationale for choosing a dilution was not discussed in the
totality of the studies; in the PRP section, the dilution was not even reported in 14 out of 18 studies
included in the analysis.
Taken altogether, data suggest that the parameters of processing and use were considered more as
an established habit of the centers over the years rather than a parameter to be tailored.
The conditions treated with blood-based eye drops are summarized in Table 1. Moderate and
severe DED, eventually associated to autoimmune diseases and oGVHD, and PED were the most
represented diseases treated with all the products. No indication on the choice of a specific product for
a specific disease was recorded in the analysis.
Inclusion criteria considered for a given patient to enter a therapeutic program with blood-based
eye drops are summarized in Figure 2. To be refractory to previous treatment (ranging from tear
substitutes to therapeutic soft contact lenses, topical steroids, and 0.05% cyclosporine) was the most
represented indication for the prescription, followed by severely impaired parameters of tear functions
and subjective symptoms of discomfort indicating severe dryness. Despite an increasing interest in
other disciplines concerning the application of blood-based products to pursue reduction of pain [124],
no indication of the prescription of blood-based eye drops focused on ocular pain relief was found.J. Clin. Med. 2019, 8, x FOR PEER REVIEW 25 of 32 
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Posology of treatment was also extremely variable, and when specified, it ranged from one drop
every hour to 3, 4, 6, 8, 10, or 12 drops/day or to scaled regimens consisting of a higher frequency
the first weeks of treatment and then decreasing. Beyond the obvious consideration that the amount
of active compounds supplied relates to the posology, it is also an issue that tear substitutes may be
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necessary in adjunct to protect the surface in case of a regimen with few drops. No indication on
eventual concurrent or rescue treatment allowed in cases of adverse events was found. No indication
on dose size was found.
One month was the most reported time of treatment (8 studies), followed by 6 weeks (6 studies),
2 months (2 studies), 3 and 6 months (5 studies each), continuously for one year and until healing (2
studies each), or unspecified (in the remaining studies). No consideration on the eventual early stop of
the treatment or on the retreatment parameters in terms of rationale to retreat and time interval of
treatment suspension was found. The recurrence rate was considered in only two studies [62,94].
Parameters considered as main outcomes are summarized in Figure 3. Reduction of subjective
symptoms and reduction of corneal damage (expressed either as reduction of staining and/or area
size) were reported in almost all the studies. Despite the supply of epitheliotrophic growth factors, the
healing time was seldom considered as an outcome in the studies.
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The metrics used to score all the parameters were inconsistent throughout the studies, making it
not possible to make a meta-analytic comparison.
9. Conclusions
Blood-based eye d ops represent an emerging treatment option of different ocular surface disorders,
as they supply a combination of active substances GFs and cytokines that mimic the function of
natural tears.
Allogeneic sources seem to represent a rising innovation, allowing to obtain a customized eye
drop on the base of the specific subtype of patients and ocular surface diseases.
However, further randomized clinical trials and internationally recognized harmonized guidelines
are still needed to provide better evidence, to improve quality of the final products, and to lead
to a more widespread use of these therapies in daily ophthalmological practice. Most importantly,
future studies need to include short-, medium-, and long-term follow-up to determine if any benefit is
maintained after treatment and for how long.
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There remains many unanswered questions regarding what might be considered optimal treatment,
sketched as “The 5 Ws (and 2 Hs) for blood-based eye drops”, as follows.
Who is the patient to be treated, in terms of disease type, severity, and stage?
Why is a blood-based treatment needed, in terms of a target indication?
When is it appropriate to prescribe blood-based therapy, as too late is not always a good option?
Where are the products dispensed? Is a national/regional program a feasible solution to
optimize resources?
What is the product of choice? Which source and preparation are targeted for a given patient?
Is a patient self-report enough, or should the clinician who prescribed the product report the course,
as surgeons do in organ transplants?
How is the product standardized in terms of processing to ensure optimal dilution, solvent,
dispenser, and storage time?
How is treatment delivered to the ocular surface, in terms of posology, dose-size modulation,
length of treatment, and number of cycles?
Preclinical studies are needed to standardize and compare blood based products, and an
interdisciplinary work with transfusional medicine specialists is imperative to share information
and competences.
Author Contributions: Conceptualization, P.V., F.B. and M.B.; methodology, F.B., M.R. and P.V.; software, M.R.
and M.P.; validation, F.B., P.V. and M.B.; resources, F.B., M.R., M.P., and G.G.; data curation, F.B., M.R. and G.G.;
writing—original draft preparation, F.B., M.R., M.B., M.P., G.G. and P.V.; writing—review and editing, P.V., G.G.
and F.B.; supervision, P.V. and F.B.
Conflicts of Interest: The authors have no conflict of interest to disclose in any of the products cited in
the manuscript.
References
1. Craig, J.P.; Nichols, K.K.; Akpek, E.K.; Caffery, B.; Dua, H.S.; Joo, C.K.; Liu, Z.; Nelson, J.D.; Nichols, J.J.;
Tsubota, K.; et al. TFOS DEWS II definition and classification report. Ocul. Surf. 2017, 15, 276–283. [CrossRef]
[PubMed]
2. Stapleton, F.; Alves, M.; Bunya, V.Y.; Jalbert, I.; Lekhanont, K.; Malet, F.; Na, K.S.; Schaumberg, D.; Uchino, M.;
Vehof, J.; et al. TFOS DEWS II epidemiology report. Ocul. Surf. 2017, 15, 334–365. [CrossRef] [PubMed]
3. Craig, J.P.; Nelson, J.D.; Azar, D.T.; Belmonte, C.; Bron, A.J.; Chauhan, S.K.; de Paiva, C.S.; Gomes, J.A.P.;
Hammitt, K.M.; Jones, L.; et al. TFOS DEWS II report executive summary. Ocul. Surf. 2017, 15, 802–812.
[CrossRef] [PubMed]
4. Benítez-Del-Castillo, J.; Labetoulle, M.; Baudouin, C.; Rolando, M.; Akova, Y.A.; Aragona, P.; Geerling, G.;
Merayo-Lloves, J.; Messmer, E.M.; Boboridis, K. Visual acuity and quality of life in dry eye disease:
Proceedings of the OCEAN group meeting. Ocul. Surf. 2017, 15, 169–178. [CrossRef] [PubMed]
5. Jones, L.; Downie, L.E.; Korb, D.; Benitez-Del-Castillo, J.M.; Dana, R.; Deng, S.X.; Dong, P.N.; Geerling, G.;
Hida, R.Y.; Liu, Y.; et al. TFOS DEWS II management and therapy report. Ocul. Surf. 2017, 15, 575–628.
[CrossRef] [PubMed]
6. Ralph, R.A.; Doane, M.G.; Dohlman, C.H. Clinical experience with a mobile ocular perfusion pump.
Arch. Ophthalmol. 1975, 93, 1039–1043. [CrossRef] [PubMed]
7. Fox, R.I.; Chan, R.; Michelson, J.B.; Belmont, J.B.; Michelson, P.E. Beneficial effect of artificial tears made with
autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984, 27, 459–461. [CrossRef]
[PubMed]
8. Soni, N.G.; Jeng, B.H. Blood-derived topical therapy for ocular surface diseases. Br. J. Ophthalmol. 2016, 100,
22–27. [CrossRef]
9. Giannaccare, G.; Versura, P.; Buzzi, M.; Primavera, L.; Pellegrini, M.; Campos, E.C. Blood derived eye drops
for the treatment of cornea and ocular surface diseases. Transfus. Apher. Sci. 2017, 56, 595–604. [CrossRef]
10. Kojima, T.; Higuchi, A.; Goto, E.; Matsumoto, Y.; Dogru, M.; Tsubota, K. Autologous serum eye drops for the
treatment of dry eye diseases. Cornea 2008, 27, S25–S30. [CrossRef]
J. Clin. Med. 2019, 8, 1478 24 of 29
11. Tsubota, K.; Goto, E.; Shimmura, S.; Shimazaki, J. Treatment of persistent corneal epithelial defect by
autologous serum application. Ophthalmology 1999, 106, 1984–1989. [CrossRef]
12. Freire, V.; Andollo, N.; Etxebarria, J.; Durán, J.A.; Morales, M.-C. In vitro effects of three blood derivatives on
human corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 2012, 53, 5571–5578. [CrossRef] [PubMed]
13. Liu, L.; Hartwig, D.; Harloff, S.; Herminghaus, P.; Wedel, T.; Kasper, K.; Geerling, G. Corneal epitheliotrophic
capacity of three different blood-derived preparations. Invest. Ophthalmol. Vis. Sci. 2006, 47, 2438–2444.
[CrossRef] [PubMed]
14. Huang, C.-J.; Sun, Y.-C.; Christopher, K.; Pai, A.S.-I.; Lu, C.-J.; Hu, F.-R.; Lin, S.-Y.; Chen, W.-L. Comparison
of corneal epitheliotrophic capacities among human platelet lysates and other blood derivatives. PLoS ONE
2017, 12, e0171008. [CrossRef] [PubMed]
15. Gipson, I.K. The ocular surface: The challenge to enable and protect vision: The Friedenwald lecture.
Invest. Ophthalmol. Vis. Sci. 2007, 48, 4391–4398. [CrossRef] [PubMed]
16. Funderburgh, J.L.; Funderburgh, M.L.; Du, Y. Stem cells in the limbal stroma. Ocul. Surf. 2016, 14, 113–120.
[CrossRef] [PubMed]
17. Geerling, G.; Maclennan, S.; Hartwig, D. Autologous serum eye drops for ocular surface disorders. Br. J.
Ophthalmol. 2004, 88, 1467–1474. [CrossRef]
18. Higuchi, A. Autologous serum and serum components. Invest. Ophthalmol. Vis. Sci. 2018, 59, DES121–DES129.
[CrossRef]
19. Drew, V.J.; Tseng, C.-L.; Seghatchian, J.; Burnouf, T. Reflections on dry eye syndrome treatment: Therapeutic
role of blood products. Front. Med. 2018, 5, 33. [CrossRef]
20. Klenkler, B.; Sheardown, H.; Jones, L. Growth factors in the tear film: Role in tissue maintenance, wound
healing, and ocular pathology. Ocul. Surf. 2007, 5, 228–239. [CrossRef]
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